For example, EpCAM was highly expressed on CTCs derived from prostate and breast tumors.[10–12] Some papers reported that the anti-EpCAM-antibody-immobilized microchips could capture the CTCs with high efficiency.[13–15] Although CTCs have been captured on microchips successfully, these systems are still not practical for clinical diagnosis, particularly for point-of-care testing. This evidence concerns the gene EPCAM and breast neoplasm.